<DOC>
	<DOCNO>NCT00830154</DOCNO>
	<brief_summary>A multicenter , randomize , 3 arm , placebo-controlled clinical trial ass efficacy , safety tolerability pagoclone adult stutter .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Pagoclone Adults With Stuttering</brief_title>
	<detailed_description>A multicenter , randomize , 3-arm , placebo control , parallel group study 24 week double blind treatment follow 8 week double blind washout long-term open-label extension phase .</detailed_description>
	<mesh_term>Stuttering</mesh_term>
	<criteria>Male female age 18 80 year present history stutter onset prior age 8 year old . Stuttering severity must notable &gt; 3 syllable stutter read cenversational task scereening least 2 % contribute individually conversational reading task . Patients unstable hematological , autoimmune , endocrine , neurological , renal , hepatic , retinal , gastrointestinal , cardiovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>stutter</keyword>
	<keyword>stutter</keyword>
	<keyword>Adults history stutter</keyword>
</DOC>